Sun Jie, Wang Yan, Wang Jue, Wu Hongwei, Xu Zhefeng, Niu Dongsheng
Department of Emergency Medicine, Jincheng People's Hospital, Jincheng, China.
Department of Respiratory and Critical Care Medicine, Jincheng General Hospital, Jincheng, China.
Front Med (Lausanne). 2024 Dec 2;11:1453522. doi: 10.3389/fmed.2024.1453522. eCollection 2024.
Vitamin D, an essential fat-soluble micronutrient, exerts diverse physiological effects including the regulation of calcium ion homeostasis, modulation of immune response, and enhancement of resistance against infectious pathogens. Empirical investigations have elucidated an association between inadequate levels of vitamin D and adverse clinical outcomes in critically ill cohorts, with a noteworthy prevalence of vitamin D deficiency observed among patients afflicted with acute kidney injury (AKI). In the context of this retrospective inquiry, our aim was to assess the potential correlation between vitamin D supplementation administered during admission to the intensive care unit (ICU) and the improvement of outcomes specifically in cases of severe AKI.
This study utilized data from the Medical Information Mart for Intensive Care IV (MIMIC-IV), a repository of ICU patient records from Beth Israel Deaconess Medical Center (BIDMC) in the United States. We focused on patients diagnosed with epsis-associated acute kidney injury (SA-AKI), dividing them into those who received vitamin D supplementation during their ICU admission and those who did not. Our primary analysis evaluated in-hospital mortality using various statistical methods, such as Kaplan-Meier survival curves, Cox proportional hazards regression models, and subgroup analyses. To enhance the robustness of our findings, we used propensity score matching (PSM) to reduce potential biases. Secondary outcomes included 28-day, 90-day mortality rates and norepinephrine-free days at 28 days.
In this investigation, a cohort of 11,896 individuals diagnosed with SA-AKI was studied. Among them, 2,724 patients received vitamin D supplementation (the vitamin D group) while 9,172 did not (the no-vitamin D group). Kaplan-Meier survival analysis indicated a significant difference in survival probabilities between the two cohorts. Upon adjusting for potential confounders using Cox regression modeling, a notably decreased risk of hospitalization and ICU mortality was observed in the vitamin D group compared to the no-vitamin D group, with an adjusted risk ratio for in-hospital mortality of 0.56 (95% CI: 0.5-0.63). These findings were consistent following PSM and subsequent adjustments for propensity score, pairwise algorithm (PA), and overlapping weights (OW) analyses, yielding hazard ratios ranging from 0.53 to 0.59, all with -values <0.001. Notably, E-value analyses underscored the robustness of these results against potential unmeasured confounders.
This study suggests that vitamin D supplementation may be associated with a reduced in-hospital mortality rate among SA-AKI patients in the ICU. Furthermore, the 28-day, 90-day mortality rates and norepinephrine days were significantly reduced in the group receiving vitamin D supplementation.
维生素D是一种必需的脂溶性微量营养素,具有多种生理作用,包括调节钙离子稳态、调节免疫反应以及增强对感染性病原体的抵抗力。实证研究已阐明重症患者中维生素D水平不足与不良临床结局之间的关联,在急性肾损伤(AKI)患者中观察到维生素D缺乏的患病率值得关注。在这项回顾性研究中,我们的目的是评估重症监护病房(ICU)入院期间补充维生素D与严重AKI患者结局改善之间的潜在相关性。
本研究利用了重症监护医学信息集市IV(MIMIC-IV)的数据,该数据库是美国贝斯以色列女执事医疗中心(BIDMC)的ICU患者记录库。我们关注被诊断为脓毒症相关性急性肾损伤(SA-AKI)的患者,将他们分为在ICU住院期间接受维生素D补充的患者和未接受补充的患者。我们的主要分析使用了各种统计方法评估院内死亡率,如Kaplan-Meier生存曲线、Cox比例风险回归模型和亚组分析。为了增强研究结果的稳健性,我们使用倾向评分匹配(PSM)来减少潜在偏差。次要结局包括28天、90天死亡率以及28天时无去甲肾上腺素使用天数。
在这项调查中,对11896名被诊断为SA-AKI的患者进行了研究。其中,2724名患者接受了维生素D补充(维生素D组),而9172名患者未接受补充(无维生素D组)。Kaplan-Meier生存分析表明两组患者的生存概率存在显著差异。使用Cox回归模型对潜在混杂因素进行调整后,与无维生素D组相比,维生素D组的住院和ICU死亡率风险显著降低,院内死亡率的调整风险比为0.56(95%CI:0.5 - 0.63)。在PSM以及随后对倾向评分、成对算法(PA)和重叠权重(OW)分析进行调整后,这些结果一致,危险比范围为0.53至0.59,所有P值均<0.001。值得注意的是,E值分析强调了这些结果对潜在未测量混杂因素的稳健性。
本研究表明,补充维生素D可能与ICU中SA-AKI患者的院内死亡率降低有关。此外,接受维生素D补充的组中28天、90天死亡率以及去甲肾上腺素使用天数显著降低。